About the Authors

Chiori Yabuki

chiori.yabuki@takeda.com

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan

Hidetoshi Komatsu

Affiliation Central Nervous System Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan

Yoshiyuki Tsujihata

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan

Risa Maeda

Affiliation Central Nervous System Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan

Ryo Ito

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan

Kae Matsuda-Nagasumi

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan

Kensuke Sakuma

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan

Kazumasa Miyawaki

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan

Naoya Kikuchi

Affiliation Central Nervous System Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan

Koji Takeuchi

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan

Yugo Habata

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan

Masaaki Mori

Affiliation Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan

Competing Interests

All authors are employees of Takeda Pharmaceutical Company Limited. Fasiglifam/TAK-875 used in our study is a product in drug development under phase 3 clinical studies, and there is a filed patent: WO 2008/001931. There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: CY HK YT YH MM. Performed the experiments: CY YT RM RI KMN KS KM NK. Analyzed the data: CY HK YT RI KS KT YH MM. Contributed reagents/materials/analysis tools: CY YT RI NK. Wrote the paper: CY HK YH MM.